Cremieux

What happens when the United States is no longer the leader in biomedical innovation?

For decades, the U.S.

dominated drug development, producing a large share of the world's new therapies and setting the pace for clinical research.

But over the last few years, that's started to change.

China has rapidly expanded its clinical trial system, accelerated approvals, and is now leading in both volume and novel drug development.

This shift isn't about scale.

It's about systems.

Regulatory design, trial structure, funding models, and incentives all shape how quickly new treatments reach patients and where innovation happens.

The question now is whether the U.S.

can adapt or whether the center of gravity for biotech continues to move.

Theo Jaffe and Gabriel Dickinson speak with CREMIU.

Sure.

Thanks for listening to this episode of the A16Z podcast.

If you liked this episode, be sure to like, comment, subscribe, leave us a rating or review, and share it with your friends and family.

For more episodes, go to YouTube, Apple Podcasts, and Spotify.

Follow us on X and A16Z, and subscribe to our sub stack at a16z.substack.com.

Thanks again for listening, and I'll see you in the next episode.

This information is for educational purposes only and is not a recommendation to buy, hold or sell any investment or financial product.

This podcast has been produced by a third party and may include paid promotional advertisements, other company references and individuals unaffiliated with A16Z.

Such advertisements, companies and individuals are not endorsed by AH Capital Management LLC, A16Z or any of its affiliates.